
Clinical Thyroidology for the Public summarizes selected research studies discussed in the previous month’s issue of Clinical Thyroidology, an official publication of the American Thyroid Association. Editor-in-chief, Alan Farwell, MD, FACE
Volume 19 Issue 11
Available in pdf format for saving and printing and Web page format for viewing online
PDF Format for Saving and Printing
Clinical Thyroidology for the Public Volume 19 Issue 11 (PDF file, 2.82 MB)
TABLE OF CONTENTS – Web Format
THYROID IN PREGNANCY
2026 American Thyroid Association guidelines for thyroid disease in pregnancy: Hypothyroidism
Thyroid hormone plays a major role in brain development of the baby during pregnancy. The 2026 ATA guidelines for thyroid disease in pregnancy represent a meaningful shift from reflex treatment toward confirming persistent hypothyroidism and individualized decision-making. The key aspects in the section on hypothyroidism have been outlined here.
Korevaar TIM, et al. American Thyroid Association 2026 guidelines for thyroid disease in preconception, pregnancy, and postpartum. Thyroid 2026;36(5):481–544; doi: 10.1177/10507256261445624. PMID: 42219800.
HYPOTHYROIDISM
Does starting levothyroxine treatment in older adults with subclinical hypothyroidism help their heart?
The association between heart disease and subclinical hypothyroidism in older adults remains unclear. Several studies suggest that subclinical hypothyroidism is associated with increases in several cardiometabolic biomarkers. However, findings remain inconsistent. The aim of this study was to evaluate the effects of levothyroxine on cardiometabolic biomarkers in older adults with subclinical hypothyroidism.
Ao L, Noordam R, Trompet S, et al. Levothyroxine treatment response of cardiometabolic biomarkers in older adults with subclinical hypothyroidism. J Clin Endocrinol Metab 2026;111(9):2445–2455; doi: 10.1210/clinem/dgag155. PMID: 41965091.
THYROID CANCER
Am I supposed to decide my thyroid cancer treatment?
Shared decision making is the standard of care in cancer settings. It is especially important in the field of thyroid cancer, since less invasive treatment methods are being recommended with recent guidelines. The goal of this study was to see if communication training by physicians and decision aids for patients helped with the practice of shared decision making.
Koot A et al. Effect of a patient decision aid on shared decision making in patients with differentiated thyroid cancer: a randomized controlled trial. Oncologist 2026;31(5)
THYROID CANCER
2025 ATA Thyroid Cancer guidelines: Percutaneous thyroid ablation—who, when, why?
Percutaneous thermal ablation, a procedure where radiowavebased (RFA) or microwave-based (MWA) heat delivered by a needle is used to destroy abnormal thyroid tissue. Recently, studies have been reported using RFA to treat small thyroid cancers without surgical resection. The 2025 guidelines formally recognize ultrasound-guided percutaneous ablation as an alternative to active surveillance or surgical resection for selected patients with small, low-risk thyroid cancer.
Ringel MD et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid 2025;35(8):841-985.
THYROID CANCER
When is the best time to remove the thyroid in children with MEN? – balancing the risks of cancer and surgery
Patients with MEN2 have a high risk of developing medullary thyroid cancer. The best approach is to remove the thyroid before the cancer develops and is usually done in childhood. However, surgery in very young children has risks. In this study, researchers evaluated the results and risks of preventive thyroid surgery in children with MEN2.
Morard I et al. Surgical morbidity and short-term oncologic status after prophylactic-intent thyroidectomy in a cohort of children with MEN2 from the multicentre GTE ENDOCAN- RENATEN study. Thyroid 2026;36(10):1137–1141; doi: 10.1177/10507256261477167. PMID: 42565336.
THYROID CANCER
Fine-tuning cancer risk and response: Practical implications of the 2025 ATA Thyroid Cancer Guidelines
The 2025 ATA guidelines make several important adjustments to risk stratification from the 2015 guidelines. However, the clinical practice implications of these new guidelines remain unknown. The present study aimed to compare cancer classification between the 2015 and the 2025 guidelines for papillary thyroid cancer and whether cancer risk redistribution corresponded with final disease outcome.
Moneta C, et al. Validation of the 2025 ATA risk stratification system in a cohort of patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2026;111(10):2883–2889

